Observational studyBMJ open2026
Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06298006 (Uppföljning av Psykiatriska, Kognitiva Och Neurologiska Symtom Hos Post COVID-19 Patienter.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Uppföljning av Psykiatriska, Kognitiva Och Neurologiska Symtom Hos Post COVID-19 Patienter.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKnowledge about the late effects of COVID-19, or so-called post-acute sequelae of COVID (PASC), and its pathogenesis is still very limited. The purpose of this observational study is to chart late neurocognitive effects of the COVID-19 infection. The aim is to increase knowledge of the underlying biological processes and describe how biomarkers correlate with degree of symptoms, mapping their role as diagnostic markers over time (24 months). METHODS AND ANALYSIS: This prospective observational cohort study is longitudinal and monitors patients with neurocognitive and psychological symptoms after COVID-19 infection in order to analyse the impact on the brain. For these purposes, we introduce a digital neuropsychological platform (Mindmore). We also aim to analyse potential diagnostic and prognostic markers from blood and cerebrospinal fluid and use MRI of the brain. We will measure the patients' return to work and studies as well as any impact on their ADL functions and quality of life. The ongoing study aims to follow-up to 100 study participants with PASC for 24 months at three visits: baseline, 12 months and 24 months. The findings of the study can be used as guidance for future policy management in healthcare and may lead to a possible curative or symptom-relieving treatment. ETHICS AND DISSEMINATION: This study was approved by the Swedish Ethical Review Authority (diary number: 2020-0604 (main application), 2021-03205, 2023-00023-02, 2024-00426-02 (amendments)). Participants will be required to provide informed consent. The results of this study will be reported in peer-reviewed journals and presented at scientific conferences. TRIAL REGISTRATION NUMBER: NCT06298006.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.